Well, off you go then. You've got the recipe and you can see there's a market so prove your point and put them out of business. See how you go breaking into the deals PHK has in place with its Chinese partners and getting all the regulatory approvals and distributors in place all over the world that any newcomer would be required to establish.
You keep harping on about the panadol example. I think Panadol are still doing pretty well for themselves actually, despite generics, whereas there is no sign anywhere of a generic competitor to PHK, which keeps getting more approvals and more agreements that make it harder for competitors to enter the market.
- Forums
- ASX - By Stock
- PET
- china
china, page-74
-
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PET (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.60M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
PET (ASX) Chart |
Day chart unavailable
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online